Related Experiment Video
Updated: Aug 22, 2025

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
Published on: October 30, 2016
BTK Inhibitors in Haematology: Beyond B Cell Malignancies
Dr Emma Leitinger1, Dr Zane Kaplan2
1Monash Haematology, Monash Health, 246 Clayton Road, Clayton, Australia.
Abstract:
Autoreactive B-cells are crucial in the pathogenesis of both haematologic and non-haematologic autoimmune disorders. Therapies targeting B cells and autoantibodies are widely used in clinical practice, however, many patients fail to respond to conventional treatments. An evolving understanding of molecular mechanisms underlying autoimmune haematologic disorders has facilitated the development of novel therapies, including Bruton's Tyrosine Kinase (BTK) inhibitors. BTK is fundamental in B-cell survival, and its inhibition has been used in a wide range of autoimmune and inflammatory conditions, as well as mature B cell malignancies. This paper reviews the role of BTK in immunity, evolution of BTK inhibitors, and the emerging evidence for BTK inhibitors in autoimmune haematologic conditions, primarily immune thrombocytopenia (ITP), and potential future clinical applications.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Inhibition of Cdk Activity
Tumor Immunotherapy
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

